James Ferguson has over 25 years of experience as a stockbroker, sector analyst and macro-economic strategist. He is a founding partner of MacroStrategy Partnership and previously held the position of Head of Strategy at Westhouse Securities Limited and Chief Strategist at Pali International. He formerly held a variety of positions, predominantly covering the Japanese market at investment banks Nomura, Robert Fleming, SBC Warburg, Dresdner Kleinwort and Mitsubishi Securities, based in London and Tokyo.
Drawing on a background in Japan, James is currently looking at the western banking crisis and the implications of policy responses for economic growth prospects. James believes that an appreciation of the Japanese experience, the build up and breaking of the western crisis is critical to steering a safe course through a multi-year resolution period.
A regular contributor to Money Week since 2004, James frequently sits on the magazine’s investment Roundtable. He has made frequent appearances on the BBC TV and radio news, as well as Sky TV, Channel 4 and Bloomberg TV commenting on economic, banking and investment matters; including co-hosting both CNBC’s Squawk Box and Worldwide Exchange programmes.
Nigel Farage will take time out from his General Election campaign to deliver a presentation that will be characterized by his straight-talking style and outspoken views. This promises to be a fascinating, cutting-edge insight into the political aspects surrounding the business world from a man who will be holding considerable political power in any future British Government.
Beaufort Securities is an award-winning traditional stockbroker incorporated nearly a quarter of a century ago. Over the last two decades it has established itself as one of the UK’s leading independent private client investment houses. In addition to advising on and buying and selling shares we also offer our clients many other solutions to satisfy their investment needs e.g. tax wrappers such as ISAs, SIPPs, bond trading and CFDs.
Prime Wealth Group is a specialist multi-product broker committed to providing a professional and personal service to each of our clients. From our offices in Mayfair, we provide a range of investment services including Contracts for Difference (“CFD”), trading with professional research and analysis, advisory equity trading and spread betting. We also offer execution-only services in all these products.
“For one day in the year I can be my own fund manager and make my own decisions as to where I want to place my investments. I’ll leave my money for a year and next year will be back to here to make the next round of investments, whether they be companies or funds. I like to feel that I am in charge of my own money”
Richard Reed is a co-founder of Innocent Drinks, the UK’s fastest growing food and drinks company and the No.1 smoothie brand in the UK. The business was started in May 1999 by Richard and two friends and now has a turnover of over £150m. Innocent has been called ‘The Ultimate 21st Century Company’ – quirky, personable, values-based and profitable and determined to remain what Reed calls a ‘big small’ company, no matter how large it grows.
Innocent drinks is not Richard’s first enterprise. In fact, Richard’s entrepreneurial career started earlier than most, when he began washing windows for his neighbours at the age of 8. Following a brief spell of selling Smurf stickers at junior school (until his teachers caught him), Richard retired from the coal-face of self-employment, aged 12. However, a summer job picking up dog biscuits in a pet food factory soon reminded Richard of the joys of working for himself, and led him to set up a summer gardening business called ‘Two Men Went to Mow’, employing his school friends.
After graduating from Cambridge University and working in advertising for four years, Richard Reed and his two college friends Jon and Adam, decided to set up a lovely fresh fruit juice company. After six months of developing recipes in their kitchen, they boys wanted to test their drinks with a wider audience. To do so, they bought £500 of fruit, turned it into smoothies and sold them from a stall at a music festival. They put up a sign that said, ‘Should we give up our jobs to make these smoothies’, and put out a big bin that said ‘NO’ and one that said ‘YES’. Fortunately, at the end of the weekend, the YES bin was full so they went to work the next day and resigned.
Innocent make a unique range of natural, healthy juices and the company now has 75% of its domestic market, sells in 10 different countries across Europe, and its products are sold in every major chain, from Sainsbury’s to Boots to Starbucks.
As well as growing Innocent, Richard Reed has been a government advisor on entrepreneurship, through round table discussions with the Prime Minister and his seat on the Small Business Council. Richard and Innocent’s awards include E&Y Young Entrepreneur of the Year, National Business Awards’ Small/Medium Business of the Year, Orange Small Business of the Year and Orange Innovative Company of the Year.
Professor Sir John Bell FRS is Regius Professor of Medicine at Oxford University, and Chairman of the Office for the Strategic Coordination of Health Research. He recently stepped down as President of the Academy of Medical Sciences (2006-2011). As a Rhodes Scholar (1975-78), Sir John undertook his medical training in the UK and then went on to Stanford University, returning to the UK in 1987. His research interests are in the area of autoimmune disease and immunology where he has contributed to the understanding of immune activation in a range of autoimmune diseases. In 1993, he founded the Wellcome Trust Centre for Human Genetics, one of the world’s leading centres for complex trait common disease genetics. In 2001, he was appointed non-executive director of Roche Holding AG and in 2008 he joined the Gates Foundation Global Health Advisory Board which he has chaired since 2012. Sir John was responsible for the working party that produced the highly influential Academy of Medical Sciences “Strengthening Clinical Research” report that highlighted the need for the UK to focus some of its attention on developing expertise in translational research. In December 2011, Sir John was appointed one of two UK Life Sciences Champions by the Prime Minister.
Terry Smith is a former number 1 rated analyst, author of bestseller Accounting for Growth, fund manager and FTSE 250 CEO. With a maverick approach and outspoken views on his own industry, he is proving he walks the walk and does not just talk it. Fundsmith was founded in 2010 as the main vehicle for his own investments, but now has over £1.6 billion under management and returned 61% in its first three years. In 2014, Fundsmith will launch an investment trust investing in the same strategy as Fundsmith’s existing equity fund, but in companies that are listed in emerging markets.
Evil Knievil, the man the Daily Mail dubbed ‘The King of the Short Sellers’, (otherwise known as Simon Cawkwell) is Britain’s most feared bear-raider. A trained accountant, he made his name exposing the fiction that were Bob Maxwell’s accounts. Evil does not give investment advice on t1ps.com but three times a week he provides his thoughts and musings in the “Evil Diaries”
John Piper, aka the Psycho Trader, has been involved with markets since his early twenties. In the late 1980s he started to trade options full time and did so right through the Crash of 1987 – an experience that stands him in good stead for markets today. For over a decade he has been the editor of The Technical Trader, the leading newsletter in the UK for those who trade futures and options markets worldwide. John is the best-selling author of numerous trading books, including The Way To Trade, the classic work on trading psychology that gets deep into the mind of the market.
Zak Mir entered the City in the early 1990s and was a derivatives broker at various companies such as Sucden, Union Cal (later part of Man Group) and Berkeley Futures.
From 2000 the growth of Technical Analysis and the opportunities presented by the Internet led to Zak being Shares Magazine’s first Technical Editor whilst also providing content to now defunct websites such as TheStreet.co.uk and UKInvest.com.
In 2001 Zak teamed up T1PS.com to found Zaks-TA.com, one of the first websites to popularise Technical Analysis in the UK and still going strong today.
Zak also provides white label research to some of the City of London’s largest retail brokers via Brand Communications (Branduk.net).
Cameron has a 15 year background in building and running multi-million pound businesses. He had great success in the business world but found he was never fully satisfied. He searched long and hard to find the ideal business for him that didn’t have the incumbents of traditional business (Offices, Stock, Warehouses etc) and would allow him the freedom he was looking for.
After years of searching, Cameron found what he was looking for in Trading the Markets and these days is a “Life Style” trader specializing in short term trading of the US Dow Jones Index. 90% of Cameron’s trades are completed within the first hour of trading.
Cameron is also the co-founder of Excelsior Trading running a market report and trading service which returned 54% in the last year. Since the launch of Cameron’s Pro Trader Mentoring program, a live trading room and educational service, in October 2013 he has returned 124% to the end of March 2014. One of Cameron’s largest trades in the room pulled in 28% in less than 30 minutes.
Alpesh Patel is the founder of UK asset management company, Praefinium Partners Ltd., with Luxembourg domiciled funds. He is the author of 18 books on investing and for 5 years wrote a weekly trading column for the Financial Times, with over 200 columns published in the paper. For three years he co-hosted investment shows on Bloomberg TV and hosted Newsbytes for Sky TV (about the politics of technology). Alpesh is a former Visiting Fellow in Business & Industry, Corpus Christi College, Oxford, and qualified as a Barrister after a degree in Law (King’s College, London) and Philosophy, Politics, Economic (St Anne’s College, Oxford). He is also associated with the British Government, the UKTI Global Entrepreneur Programme Dealmaker, responsible for India and China, a role in which he looks to make deals for outstanding IP and entrepreneurs to land in the UK for their global HQ….
Paul Kavanagh is a Partner and Senior Market Strategist at Killik & Co, the advisory stockbroker and wealth manager he joined in 1993.
He is also Chairman of Killik Capital, the division of the firm which caters for the more high-risk, sophisticated investor through products including CFDs, Spreadbetting, Managed Futures and Special Situations.
Paul is a respected commentator on the markets and the economy, regularly appearing in the financial pages of the weekend press as well as on the BBC’s ‘Today’ programme, ITV’s Daybreak and CNBC. He shares his market thoughts in a podcast released each week.
Alluvia Mining Limited is a diversified precious metals development and mining company. With a strategy to identify high-quality, undervalued assets with growth potential on a large scale. The company has majority ownership of Gold concessions in Denver Colorado, Suriname and Chile. The company benefits from the exclusive rights to 30 plants of a tested and proven patented mining technology process, capable of achieving increased recoveries, at low cost, in an environmentally friendly manner that decreases water usage and enables continuous land reclamation.
Synergy Pharmaceuticals Inc., headquartered in New York, NY with research laboratories in Doylestown, PA, is a biopharmaceutical company focused on the development of novel drugs for the treatment of gastrointestinal (GI) diseases and disorders. Synergy has discovered proprietary analogs of the human GI hormone, uroguanylin, the natural agonist for the intestinal guanylate cyclase-C (GC-C) receptor. Both Synergy’s lead GC-C agonist, plecanatide, and next-generation GC-C agonist, SP-333, mimic uroguanylin’s natural functions by binding to and activating the GC-C receptor in the GI tract to stimulate fluid and transit required for normal bowel function. Plecanatide is in phase 3 clinical trials for chronic idiopathic constipation and a phase 2b study for irritable bowel syndrome with constipation. SP-333 is in phase 2 development for opioid-induced constipation and is also being explored for ulcerative colitis.
Cytox is a UK-based company with a unique scientific and proprietary technology. We are developing blood tests to identify individuals at risk of cognitive decline, Alzheimer’s disease and other dementias and are conducting two pivotal research studies in 2014 in partnership with key global experts. We have secured over £5 million investment from two rounds in the past 18 months and long term revenue projections are driven by global prevalence of Alzheimer’s disease, which is estimated to exceed 115 million by 2015.
Merryn Somerset Webb is Editor-in-Chief of MoneyWeek and a respected commentator on economics, financial markets and personal finance.
Merryn was a senior scholar at Gonville and Caius College, Cambridge, where she gained a first class degree in history & economics. She then became a Daiwa scholar and spent a year studying Japanese at London University.
In 1992 Merryn moved to Japan to produce business programmes for NHK, Japan’s public TV station. In 1993 she became an institutional broker for SBC Warburg, where she stayed for 5 years.
Returning to the UK in 1998, Merryn became a financial writer for The Week. Two years later, in 2000, MoneyWeek was launched and Merryn took the job of editor; she was recently appointed MoneyWeek’s Editor-in-Chief.
Merryn has published a book on personal finance for women, ‘Love is Not Enough: The Smart Woman’s Guide to Making (and Keeping) Money’.
Nigel Farage is UKIP MEP for the South East of England. He was re-elected Leader of the Party in 2010 with 60% of the vote.
First elected to the European Parliament in 1999, he has used his experience of the EU to increase awareness of its activities back home in Britain.
A firm believer in independence for the UK, he is a proponent of free speech and has faced considerable hostilities from his political opponents for speaking out in favour of free and fair referendums on the transfer of powers from elected politicians to the EU.
Nigel started life in the City of London, working at Drexell Burnham and Credit Lyonais Rouse before setting up his own company as a metals broker.
He became a founder member of UKIP in 1993 and has gone on to become the Party’s best known figure. Nigel has spent his life battling for what he believes are the best interests of this country.
No one could accuse Nigel of having an easy life. A near fatal car crash and a bout of testicular cancer in his early 20s, he almost lost his life in a plane crash on polling day 2010.
In his rare spare time he likes fishing, country sports and traditional English pubs. However, most of his time is spent travelling around the country and across the world talking about the European Union.
He has written his autobiography, Fighting Bull, and a second edition, Flying Free, was published recently.
Tim Price is a partner and Director of Investment at PFP Wealth Management, the discretionary asset management arm of the PFP group. PFP Wealth Management specialises in capital preservation, absolute return investment using multiple asset classes.
Tim has over 20 years’ experience of both institutional and private client wealth management, having served as Chief Investment Officer at a number of private banks. He has been shortlisted for five successive years in the Private Asset Managers Awards programme and has previously won in the category of Defensive Investing. Tim is also a regular columnist for Money Week magazine and he writes frequently for the financial media.
Dr. Andy Richards is an Entrepreneur and Angel Investor specialising in life sciences. He is currently Chairman of Altacor, Abcodia, Novacta and Ixico; Non-Executive Director of Summit, Arecor, PsychologyOn-line and is founder and special advisor to Vectura plc. In addition, he is a Non Executive Director of Cancer Research Technologies (the commercial arm of CR-UK) and Babraham Bioscience Technologies, is a member of the BBSRC Council and a Trustee of the British Science Association. He is a founder member of Cambridge Angels and an advisor to several Venture Capital Funds, Private Equity Funds and Corporate Venture Funds.
Andy is a Cambridge graduate with a PhD in enzyme chemistry who spent his early career with ICI (now AstraZeneca) and with PA Technology. He was a founder of Chiroscience and an executive director through to the sale to Celltech in 1999. Andy has a track record as a founder and active investor in more than 20 innovative healthcare and life-science companies. Many of these companies including Chiroscience, Vectura, Arakis, Altacor, Sirus, Pharmakodex and Theradeas have had repositioning, reprofiling and drug delivery as key elements of their business model. This has led to a major involvement in 3 repositioned drugs that have reached the market and a further 20 that have entered clinical development with more than 10 licensing deals concluded on these programmes.